Efficacy and safety of PARP inhibitor maintenance therapy in elderly ovarian cancer patients: a real-world single-center retrospective cohort study - Takeaways - MDSpire

Efficacy and safety of PARP inhibitor maintenance therapy in elderly ovarian cancer patients: a real-world single-center retrospective cohort study

  • By

  • Jingjing Lu

  • Xuelian Song

  • Chen Zhang

  • Yi Zhu

  • Huarui Yang

  • Yi Li

  • June 8, 2026

  • 0 min

Share

  • 1

    PARP inhibitors, olaparib and niraparib, are effective maintenance therapies for elderly patients with ovarian cancer.

  • 2

    In a study of 56 patients aged 65 and older, median progression-free survival was 24 months for first-line maintenance therapy.

  • 3

    Clinical factors such as R0 status, BRCA mutation, and CA-125 levels were predictive of longer progression-free survival.

  • 4

    Anemia and thrombocytopenia were the most common grade 3–4 adverse events associated with olaparib and niraparib, respectively.

  • 5

    Long-term use of PARP inhibitors was generally well-tolerated, with lower termination rates observed for niraparib compared to olaparib.

Original Source(s)

Efficacy and safety of PARP inhibitor maintenance therapy in elderly ovarian cancer patients: a real-world single-center retrospective cohort study

  • by Jingjing Lu, Xuelian Song, Chen Zhang, Yi Zhu, Huarui Yang, Yi Li

  • June 8, 2026

Related Content

Polysaccharides-gut microbiota interaction: mechanisms regulating the hepatocellular carcinoma immune microenvironment

Alkaloids mediated regulation of microRNA in cancer: molecular insights and emerging therapeutic strategies

Safety and efficacy of cytokine-induced killer cells for gastric cancer: a systematic review and meta-analysis